Status:
COMPLETED
A Phase 1 Study of MP-424, Peginterferon Alfa 2b, and Ribavirin in Hepatitis C
Lead Sponsor:
Tanabe Pharma Corporation
Collaborating Sponsors:
Vertex Pharmaceuticals Incorporated
Conditions:
Hepatitis C
Eligibility:
All Genders
20-65 years
Phase:
PHASE1
Brief Summary
The purpose of this study is to assess the safety, pharmacokinetics, HCV RNA kinetics, and other viral characteristics after administration of two arms of MP-424 in combination with Peginterferon Alfa...
Eligibility Criteria
Inclusion
- Patients diagnosed with genotype 1b chronic hepatitis C
Exclusion
- Patients diagnosed with decompensated cirrhosis
- Patients diagnosed with positive HBs antigen in the test
Key Trial Info
Start Date :
April 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2009
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT00630058
Start Date
April 1 2008
End Date
March 1 2009
Last Update
January 6 2026
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Toranomon Hospital
Kawasaki, Takatsu-ku, Japan